“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease

€2.42

SKU: product-article-11015 Category: General

Description
Reviews (0)

Description

Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease

Reviews

There are no reviews yet.

Be the first to review “Article: Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease”

Top

Article: Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease

Description

Reviews

Related products

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Highlights in melanoma

Article: INTRODUCTION

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma